Novartis acquires Tourmaline Bio from the US
Swiss pharmaceutical company Novartis is buying in the United States. The biopharmaceutical company Tourmaline Bio is to be acquired for around $1.4 billion (CHF1.1 billion).
Select your language
Generated with artificial intelligence.
Listening:
Novartis acquires Tourmaline Bio from the US
+Get the most important news from Switzerland in your inbox
Novartis is offering $48 per share in cash, it said in a statement on Tuesday. The transaction is expected to close in the fourth quarter of 2025.
Tourmaline Bio has developed Pacibekitug, a promising monoclonal antibody against systemic inflammation, a major risk factor for cardiovascular disease. The drug is already in advanced Phase 2 trials.
+ How Novartis got ahead on ‘incredible’ cancer breakthrough
According to the press release, Novartis is thus likely to acquire a phase 3-capable product that complements its own portfolio in the field of cardiovascular diseases.
Translated from German by DeepL/ts
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.